PhD Scientific Days 2024

Poster Session J - Pathological and Oncological Sciences 1.

Effects of Blunting Annexin A1 Expression in Small Cell Lung Cancer Cell Lines

Előadó neve

Dr. Paál, Ágnes

Neptun code

E8NM06

Előadó munkahelye

MTA-SE System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University

Előadó telefonszáma

06205204926

Előadó e-mail címe

paal.agnes@semmelweis.hu

Az előadás címe

Effects of Blunting Annexin A1 Expression in Small Cell Lung Cancer Cell Lines

Szerző(k) neve és munkahelye

Paál Ágnes^1,2, Takács Ákos³, Varga V. Zoltán^1,2,3, Peták István³, Kovács Tamás^1,2,3, Ferdinandy Péter³, Görbe Anikó³, Dóra Dávid⁴

1: HCEMM-SU Cardiometabolic Immunology Research Group, Department of Pharmacology and Pharmacotherapy, Budapest, Hungary
2: MTA-SE Momentum Cardio-Oncology and Cardioimmunology Research Group, Budapest, Hungary
3: MTA-SE System Pharmacology Research Group, Department of Pharmacology and Pharmacotherapy, Semmelweis University
4: Department of Anatomy, Histology and Embryology, Faculty of Medicine, Semmelweis University

Bemutatás módja

Poszter

Szekció

Poster Session J - Pathological and Oncological Sciences 1.

Language of the presentation

Hungarian

Preferred session

Pathological and Oncological Sciences

Összefoglaló szövege

Introduction
Small cell lung cancer (SCLC) is one of the malignancies with the worst prognosis, for which there have been no major breakthroughs in treatment for a long time. Therefore, characterization of molecular mechanisms behind therapy resistance has relevance in finding novel therapeutic approaches. There are studies showing direct effects of annexin A1 (ANXA1) modulation on cancer cell proliferation. We aimed to investigate the effects of silencing ANXA1 expression in an SCLC cell line.
Aims
We hypothesized that silencing ANXA1 expression in cell culture influences malignant phenotype in vitro, such as growth rate and epithelio-mesenchymal transition, which could highlight roles of ANXA1 in SCLC therapy outcome.
Methods
An SCLC cell line with high ANXA1 expression (H1048) was transfected with control or ANXA1 silencing Lentiviral short hairpin RNA vector. As a selection agent, 0,1% puromycin was present in culture medium. Success of ANXA1 silencing was tested with western blot. Growth rate of control transfected and ANXA1 silenced cells was compared with 120-hour-long trypan blue exclusion assay. Expression of mesenchymal markers, vimentin and ß-catenin was evaluated with western blot. Statistical analysis was done with two-way ANOVA for the trypan blue assay, and one-way ANOVA for the western blots. The n number of the groups was 7-8 (n=7-8) in each experiment.
Result
Annexin A1 expression was stably silenced with Lentiviral shRNA vector, shown by western blots. Growth rate of ANXA1 silenced cells was unexpectedly higher than the native and control shRNA transfected SCLC cells. ANXA1-silenced cells showed less mesenchymal morphology in culture, which observation was supported by decreased mesenchymal marker expression on western blots.
Conclusion
Modulation of ANXA1 expression resulted in mixed effects on the SCLC cell line used. An inhibitory effect on growth rate was not detected in H1048 cell line, which suggests that annexin A1 is probably not an optimal therapeutic target. However, decreased mesenchymal phenotype of ANXA1-silenced cells is a feature that supports complex mechanisms in aggressiveness of this cancer, demanding further research.
Funding
RRF-2.3.1-21-2022-00003, Horizon 2020 No. 739593, Momentum Research Grant Hungarian Academy of Sciences LP-2021-38 to ZVV, NKFIH of Hungary K139237 to AG, SE250+ Excellence Fellowship to ÁP

University

Semmelweis University

Supervisor

Görbe Anikó

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

7414

Start

16:50

End

16:53